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Congenital syphilis is the oldest recognized congenital infection, and continues to account for extensive global perinatal morbidity
and mortality today. Serious adverse pregnancy outcomes caused by maternal syphilis infection are prevented with screening early
in pregnancy and prompt treatment of women testing positive. Intramuscular penicillin, an inexpensive antibiotic on the essential
medicine list of nations all over the world, eﬀectively cures infection and prevents congenital syphilis. In fact, at a cost of $11–15
per disability adjusted life year (DALY) averted, maternal syphilis screening and treatment is among the most cost-eﬀective public
health interventions in existence. Yet implementation of this basic public health intervention is sporadic in countries with highest
congenital syphilis burden. We discuss the global burden of this devastating disease, current progress and ongoing challenges for
its elimination in countries with highest prevalence, and next steps in ensuring a world free of preventable perinatal deaths caused
by syphilis.
1.Introduction
Mother-to-child transmission of syphilis, that is, congenital
syphilis, has been documented since the 15th century [1],
yet continues today to cause substantial perinatal morbidity.
If left untreated, maternal syphilis infection will, in up
to 80% of pregnancies, lead to severely adverse pregnancy
outcomes including stillbirth, premature birth, neonatal
death, or congenital infection in the newborn [2]. In
light of continuing perinatal mortality caused by syphilis
and the high cost-eﬀectiveness of antenatal screening and
treatment as an intervention package [3], in 2007 the World
Health Organization (WHO) launched a global initiative
for the elimination of congenital syphilis. In subsequent
analyses, WHO has estimated that, were ten countries with
high antenatal syphilis burden allowed to focus eﬀorts in
strengthening existing maternal and child health (MCH)
systems infrastructure to ensure universal maternal syphilis
screening coupled with prompt treatment, an investment of
only $3 to 4 million dollars per year over ﬁve years could
substantiallyreducethisglobalperinatalscourge.Inaddition
to these resources, elimination of congenital syphilis requires
a combined commitment of governments and other partners
i no r d e rt om o u n ta ne ﬀective and sustained response.
The global elimination of congenital syphilis can greatly
support current global eﬀorts, including those outlined
in the Millennium Development Goals of reducing child
mortality, improving maternal health, and combating HIV,
malaria and other infectious diseases.
2. Global Burden of Congenital Syphilis
Globally just over 2 million pregnant women test positive for
syphilis each year, comprising 1.5 percent of all pregnancies
worldwide [9, 10]. Treponema pallidum, the bacteria causing
syphilis, is able to traverse the placenta early in pregnancy
and lead to fetal exposure; however, fetal compromise is
generally not manifested until later in the second or third
trimesters with maturation of the fetal immune system
[2]. Cohort studies have been consistent in ﬁnding that2 Obstetrics and Gynecology International
Table 1: Adverse pregnancy outcomes due to maternal syphilis.
Outcome Harmon [4] Ingraham [5]R a b u t [ 6] McDermott [7] Watson-Jones [8]
(N = 1001) (N = 302) (N = 722) (N = 436) (N = 100)
Stillbirth 17% 22% 36% 46% 25%
Neonatal Death 23% 12% 35% NA
Prematurity or low birth weight NA NA NA NA 25%
Infected Infant 21% 33% NA NA NA
Any adverse outcome 61% 67% 36% 81% 49%
NA = Data not assessed.
substantial proportions (40–81 percent) of syphilis-exposed
fetuses are severely aﬀected, with stillbirth neonatal death
being the most signiﬁcant consequences (Table 1)[ 4–8]. A
smaller but substantial proportion of untreated maternal
infections results in congenital infection in newborn infants,
often manifested by premature birth, low birth weight,
and failure to thrive. Among surviving infants, visceral
involvement is common, as are fever, rashes, blindness, and a
variety of typical skeletal and dental abnormalities [1].
The World Health Organization (WHO) estimates that
globally the majority of maternal syphilis infections are
untreated and of suﬃciently high-titer (RPR ≥ 1:8)tocause
signiﬁcantfetalexposuretoT. pallidum. Thissituationresults
in an estimated 692,100 to 1.53 million adverse pregnancy
outcomes each year caused by syphilis (Table 2)[ 8, 11–13].
Approximately 650,000 of these pregnancy complications
result in perinatal deaths (i.e., deaths occurring from 22
weeks gestation through the ﬁrst 7 days of life). Thus,
untreated maternal syphilis is believed to have at least similar
mortality, if not higher, than other important infections
during pregnancy such as HIV (estimated to cause 250,000–
290,000 perinatal deaths globally) [14]n e o n a t a lt e t a n u s
(200,000 perinatal deaths), or malaria in pregnancy (200,000
perinatal deaths) [13]. Globally, untreated maternal syphilis
infection accounts for up to one quarter of all stillbirths
and 11% of neonatal deaths, with most of these perinatal
deaths occurring in developing settings with moderate or
high antenatal syphilis prevalence and weak health systems
[15].
3.Situation:Health ServicesDeliveryNow
Adverse pregnancy outcomes caused by syphilis can be
almost entirely averted through early identiﬁcation of mater-
nal infections through antenatal screening programmes, and
prompt treatment of women with positive tests with a single
doseoflongactingpenicillinpriorto24weeksgestation[16].
Maternal syphilis screening and treatment are recognized
as part of essential antenatal services [17], and almost
all nations already have existing policies recommending
universalsyphilisscreeningduringpregnancy[18].However,
implementation of the policy is weak in many settings,
particularly in countries with highest disease burden.
High-burden countries have reported numerous barriers
that limit eﬀective screening and treatment as part of basic
antenatal health services [19]. Access to early antenatal clin-
ical (ANC) services, especially prior to 24 weeks gestation,
Table 2: Estimated global burden of congenital syphilis cases.
Proportion of
seropositive women
with:
Watson-Jones
[8, 11]
Schulz
[12]
WHO
[13]
Untreated syphilis 95%∗ 100% 100%
High serologic titer
(≥1:8) 73% — —
Adverse pregnancy
outcome due to
syphilis∗∗
49% 65% 75%
Global Annual No. of
Congenital Syphilis
Cases
692,100 1,323,900 1,527,600
Note that all assumptions based on WHO estimate of 2,036,753 pregnant
women with syphilis [9].
∗notincludedintheoriginalWatson-Jonesmodel; ∗∗includeslatefetalloss,
perinatal death, prematurity/low birth weight, neonatal infection.
is still limited in many parts of the world, and particularly
in sub-Saharan African nations where a third of women
either receive care later in pregnancy or do not receive care
at all [17]. Health providers, particularly those in lower-
level health facilities, may be unaware of the burden of
congenital syphilis or the need to identify and treat early in
pregnancy, and thus may not prioritize syphilis screening for
theﬁrstantenatalvisit. Syphilis diagnosis canbe complicated
andusuallyrequires serologic screening with nontreponemal
(e.g., RPR) or treponemal (e.g., TPHA) tests, and ideally
both. While RPR tests, measuring active infection, are rela-
tively simple and inexpensive, they require basic laboratory
capacity, trained technical staﬀ, and ongoing quality control
systems. Unfortunately many lower-level facilities providing
antenatal services have no laboratory access, thus testing is
often simply not done at all. In antenatal facilities with access
to laboratories able to conduct RPR tests (typically district
level or higher facilities), women must often go to a separate
site for testing, incurring additional transportation costs and
waiting time above the basic antenatal visit. Additionally,
women are often asked to pay for the tests themselves, a
substantial barrier for many women [17, 20–23].
Even in places that could feasibly provide testing rou-
tinely,furthersystemslevelissuessuchasstockoutsofcritical
commodities and inadequate numbers or distribution of
clinical or laboratory providers can limit testing. Also,
for women with positive tests, treatment can be delayed
when results are not provided in a timely fashion, orObstetrics and Gynecology International 3
when treatment is diﬃcult to access. Women with positive
screening tests may not learn about positive results until a
later clinic visit, and are often asked to travel to another
site for treatment—for which they often, again, have to pay
themselves. Furthermore, while most programmes collect
data on maternal screening, few collect data on provision or
timing of treatment, and thus programmes may be unaware
of their deﬁciencies in providing prompt and appropriate
treatment [22, 23]. Another increasingly reported barrier
that limits programme coverage and eﬀectiveness is the
provision of disease-speciﬁc antenatal care. In some settings
women are required to attend diﬀerent clinics for basic ANC
services, HIV testing and prevention of mother to child
transmission services(PMTCT),andmalaria prevention and
treatment, for example [23].
4. WHO Initiativefor the Global
Eliminationof CongenitalSyphilis
4.1. Rationale and Strategy. Taking into consideration the
current challenges to congenital syphilis prevention, WHO
has outlined a strategic plan of action for the global elimina-
tion of congenital syphilis [20] as a public health problem.
Given diﬃculties in diagnosing and monitoring syphilis-
related complications, the speciﬁc goal of this elimination
eﬀort is to prevent transmission of syphilis from mother to
child. This can be achieved by strengthening antenatal care
programmes to ensure that all women receive early antenatal
care which includes universal syphilis screening, prompt and
appropriate treatment, and counselling on how to prevent
infection. Additionally, recommendations that partners of
infected women are treated (reducing reinfection) and that
all neonates born to infected mothers are treated will help
reduce congenital syphilis in live borne infants.
WHO has also outlined a series of guiding principles
upon which the global congenital syphilis elimination strat-
egy was developed: country-driven to adapt to local needs;
integrated to ensure that the eﬀort strengthens existing
STI, HIV, prenatal, and maternal and newborn health
services; rights-based to ensure that all individuals have the
knowledge to participate in decision-making about their
health and access to high-quality care, and collaborative so
that government bodies, donors, and communities work
together to optimize use of scarce resources.
At a country level, WHO outlined a strategy consisting of
four pillars with corresponding speciﬁc objectives of actions
to be undertaken (Figure 1). The pillars are the following:
(1) ensure advocacy and sustained political commitment
for a successful health initiative,
(2) increase access to, and quality of, maternal and
newborn health services,
(3) screen and treat pregnant women and partners, and
(4) establish surveillance, monitoring, and evaluation
systems.
The global initiative emphasizes that congenital syphilis
elimination can contribute directly to three of the Mil-
lennium Development Goals (MDGs) by reducing child
mortality (MDG4) through reductions in perinatal deaths
and low-birth-weight infants; improving maternal health
(MDG5)throughreductionsinlatefetallossesandstillbirths
and through a decreased burden of syphilis in pregnant
women, and combating HIV/AIDS, malaria and other
diseases (MDG6) through combined, systematic screening
for HIV and syphilis in pregnancy with an emphasis on
strengthening antenatal and postpartum health systems.
4.2. Measuring National and Local Programme Progress and
Impact. Although some countries routinely monitor reports
of congenital syphilis as a routine part of public health
reporting, in general, case reporting of congenital syphilis
is problematic as its deﬁnitive diagnosis is not easy. To
address this, a WHO-led working group has identiﬁed a
set of outcome and process indicators that together are
feasible measures of programme progress and impact on
congenital syphilis elimination. Monitoring the proportion
of stillbirths attributable to syphilis was identiﬁed by the
working group as the most promising outcome indicator,
and it was recommended that a target for nations should be
that “the proportion of stillbirths attributable to syphilis in
the mother be less than 2 percent.”
T h es t i l l b i r t ht a r g e to f2p e r c e n tw a sc h o s e nb e c a u s e
stillbirth is both the most common and most severe outcome
caused by untreated maternal syphilis. Among women with
active syphilis, 17 to 40 percent of pregnancies result in
stillbirth, and the risk of stillbirth has been reported as ten
to 18 times the background rate of stillbirth (approximately
2p e r c e n t )[ 4–8]. In settings with moderate to high maternal
syphilis prevalence, congenital syphilis has been reported
to account for more than 20 percent of all stillbirths (i.e.,
attributable fraction) [7, 8]. The 2 percent target was chosen
as both an aspirational benchmark and one that, historically,
wasabletobeachievedinsettingsadoptinguniversalsyphilis
screeninginpregnantwomenandprompttreatmentofthose
testing positive [5, 6].
Three critical process indicators were also identiﬁed to
monitor programme progress, all involving collection of
local data. These are (1) the proportion of women tested for
syphilisattheirﬁrstantenatalcarevisit,(2)theproportionof
pregnant women with a positive test for syphilis, and (3) the
proportion of positive women treated for syphilis, ideally by
24 weeks. These few process indicators, along with currently
collectedindicatorsonestimatednumberofpregnanciesand
coverage of antenatal screening, potentially allow countries
to calculate a summary process indicator that estimates
overall programme eﬀectiveness, that is “the estimated
proportion of all syphilis-positive pregnant women treated
by 24 weeks of gestational age.” This indicator is important
for countries to ascertain since treatment suﬃciently early in
p r e g n a n c y( p r i o rt o2 4t o2 8w e e k s )i sn e c e s s a r yt oa v e r tt h e
adverseeﬀectsofsyphilisinpregnancyinmostsituations[8].
5. Call to Action: An Investment Case for
EliminatingCongenital Syphilis
In order to raise funds for the goal of eliminating con-
genital syphilis, WHO and its partners have developed4 Obstetrics and Gynecology International
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Figure 1: The four pillar strategy for elimination Congenital Syphilis.
an Investment Case for resource mobilization and to raise
awareness of the issue and the proposed solutions. Cost
calculations within the Investment Case have highlighted the
signiﬁcant DALY burden associated with untreated syphilis
in pregnant women and have demonstrated how this DALY
burdendisproportionatelyaﬀectspeopleinlow-andmiddle-
income countries. The Investment Case shows how the
eliminationofcongenitalsyphilisisarelatively“easywin”for
programmes in aﬀected countries as the intervention is rel-
atively simple, highly cost-eﬀective, technically feasible, and
already politically acceptable (as demonstrated by consistent
policies already in existence). Moreover, the Investment Case
stresses that elimination of congenital syphilis is timely
for countries that are aiming to reach their Millennium
Development Goal commitments by 2015.
6. Next Steps
With suﬃcient resources, several additional areas can be
better addressed to ensure that public health eﬀorts aimed
at the global elimination of congenital syphilis are eﬀective,
sustainable, and support overall MCH systems strengthen-
ing.
6.1. Addressing Barriers and Ensuring Sustainability of Pro-
grammes. As noted, a number of barriers currently exist
that limit maternal syphilis screening and treatment eﬀorts
in developing world settings. Despite this situation, evi-
dence based on current programmes supports that many
of these barriers can be eﬀectively countered if resources
and eﬀorts focus on antenatal health systems strengthening
[22, 23]. An important component of the global initiative
to eliminate congenital syphilis is that it promotes maternal
syphilis screening and treatment as part of basic antenatal
health services, thus is framed as a means of strengthening
overall MCH systems rather than only battling congenital
syphilis. In its promotion of early antenatal care with
the recommended basic package of health services, the
initiative intervenes against a range of preventable causes of
perinatal morbidity and mortality. Similarly, in promoting
integration of ANC service delivery through strategies such
as incorporating integrated professional training and cur-
ricula for health care providers, coordinating distribution
systems for critical commodities around ANC services, or
integrating data systems monitoring, the initiative sup-
ports building capacity for improved antenatal outcomes
overall.Obstetrics and Gynecology International 5
Health service research studies have identiﬁed that
another means of ensuring sustainability of programmes
is through decentralization of laboratory services, such as
provision of same day testing and treatment through rapid
point-of-care tests [17, 20–23]. Several such tests that are
heat stable, easy to use, and low cost ($0.19–0.99 per test)
have been found to be sensitive and speciﬁc in very basic
clinicsettings[21,22].Useofsuchpoint-of-caretestsensures
women with positive results are treated as early as possible,
minimizing loss to followup and maximizing the potential
to avert pregnancy complications. Currently available point-
of-care syphilis tests are all treponemal tests, identifying any
prior infection (even previously treated cases) as opposed to
active infection. This can result in overtreatment of women
whose prior infections were already treated. Nonetheless,
studies conducted in antenatal settings lacking suﬃcient
laboratory capacity for RPR testing have found introduction
of point-of-care tests greatly enhanced screening rates [22–
24], was acceptable and had negligible risks for women [23,
24], and was highly cost-eﬀective even taking into account
some overtreatment [24].
Another commonly reported barrier has been a require-
ment that screening and treatment costs are borne by the
patient. Provision of free-of-charge or low-cost testing and
treatment through government programmes has proven
important in some settings to ensure the highest risk women
are eﬀectively screened and, if positive, treated [23]. This
policy has been found to support health worker’s ability to
provide syphilis screening as a routine part of antenatal care,
solidifying the habit of universal screening, also important in
sustainability [23].
An especially diﬃcult barrier to surmount in many
settings is ensuring adequate human resources. In particular,
shortfalls in clinical faculty and the absence of training and
student mentoring opportunities can complicate strategies
for eliminating congenital syphilis. As a result, medical,
nursing and midwifery trainees not only lack updated
professional curricula and learning materials (e.g., on rapid,
point-of-care treponemal tests and syphilis treatment algo-
rithms) but also lack practical experience. Addressing this
requires the inclusion of current curricula and protocols
within pre-service education as well as taking opportunities
to observe and provide holistic antenatal care in which
syphilis prevention and treatment are incorporated into
service delivery. Equally important is engaging national
accreditation and credentialing bodies in eﬀorts focused
on the elimination of congenital syphilis. An additional
opportunity for inﬂuencing provider practice is through
partnering with global professional associations, such as,
the International Federation of Gynecology and Obstetrics
(FIGO), the International Confederation of Midwives (ICM)
and the International Council of Nurses (ICN). Such orga-
nizations are vested in advancing global standards of care
within their respective profession and can greatly inﬂuence
syphilis prevention (and its appropriate adaptation) in high-
burden countries.
6.2. Health Systems Strengthening. Supporting the creation
of strong, sustainable health systems that are responsive,
eﬃcient and equitable is now recognized as a key component
of improving health for all [25–27]. The 2005 “Paris
Declaration on Aid Eﬀectiveness” emphasizes such health
systems strengthening through local ownership (of the inter-
vention), support of local health systems, harmonization
of donor investment (thereby avoiding duplication), results
measurement, and agreement of mutual accountability for
attainment of development objectives [28]. Similar with
other health initiatives, WHO has addressed this in some
detail in the four pillar strategy identiﬁed for the global
initiative for the elimination of congenital syphilis [20].
However, an inherent challenge lies in striking an appro-
priate balance between achieving programme and disease-
speciﬁc goals while at the same time ensuring long-term
sustainability through well-functioning and adequately-
resourced health systems. This challenge also provides an
opportunity in that investments that strengthen health
systems can be leveraged to ensure that, in nations with
high perinatal morbidity, congenital syphilis interventions
are part of the comprehensive MCH systems strengthening
eﬀorts. Similarly, partnering with other global health initia-
tives such as the Global Fund (To Fight AIDS, Tuberculosis
and Malaria) [25] and the President’s Emergency Plan for
AIDS Relief (PEPFAR) [26] can help support congenital
syphilis interventions that are provided to the same at-
risk population. The shared goals of improved infant and
maternal health encompass the areas of service delivery,
healthy workforce development, information needs, medical
products and technologies, ﬁnancing, leadership, and gover-
nance [27].
7. Summary
Untreated maternal syphilis infection continues to account
for large numbers of perinatal deaths worldwide, primarily
in nations with moderate to high community prevalence of
syphilis and weak health systems. These perinatal deaths are
preventable with suﬃciently early antenatal syphilis screen-
ing and prompt treatment of women testing positive. This
highly cost-eﬀective intervention has been demonstrated
to be successfully achieved in several high-burden settings
through strengthening current health systems. Now—in
the context of Millennium Development Goals aimed at
promoting infant health and averting preventable deaths—
is a prime opportunity to address this old disease through
promoting stronger antenatal health systems.
The 2007 WHO initiative for the global elimination of
congenital syphilis provides a framework for this eﬀort. The
monitoring and evaluation plan developed with support
from representatives of high-burden nations provides a
means of ensuring progress and accountability through
enhancing existing data systems. In addition, the Investment
Case developed by WHO and partners oﬀers a potential to
identify the resources needed to achieve congenital syphilis
eliminationoverthenextﬁveyearsintenoftheworld’shigh-
est burden countries. Evaluations of current programmes
havehelpedidentifyseveraloftheexisting barrierstocurrent
maternal syphilis screening and treatment eﬀorts as well
as potential solutions to address them. Key among these6 Obstetrics and Gynecology International
is a need to support overall health systems strengthening.
Now remains the important step of bringing this eﬀort
to fruition through integration with other programmes,
often disease-speciﬁc eﬀorts, aimed at reducing maternal
and infant morbidity and mortality. Eﬀective partnerships,
provider training, and empowerment can help support this
critical process aimed at improving overall infant health.
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